{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015582","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.109188+00:00","generated_at":"2026-06-24T02:46:49.383712+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Clearside Biomedical enters royalty financing with HealthCare Royalty for up to $65M","bullets":["Upfront cash of $32.5M; additional $12.5M escrow tied to XIPERE sales milestone, plus up to $20M second milestone.","HealthCare Royalty receives royalties from XIPERE and SCS Microinjector license deals until 2.5x (or 3.4x) payback achieved.","Proceeds intended to support CLS-AX (axitinib injectable suspension) clinical program via suprachoroidal injection.","Deal excludes Clearside's internal pipeline and future in-licensed assets; non-dilutive capital.","Transaction expected to close in August 2022; JMP Securities acted as financial advisor."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015582","json":"https://secwatch.observer/filing/0000950170-22-015582.json","markdown":"https://secwatch.observer/filing/0000950170-22-015582.md","text":"https://secwatch.observer/filing/0000950170-22-015582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022015582/0000950170-22-015582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022015582/clsd-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:46:49.383712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}